Zhen Su, CEO and Entrepreneur at Marengo Therapeutics, shared a post on LinkedIn:
“Excited to see the continued momentum around combination therapies at AACR 2026.
At Marengo, we’ve long believed that tackling cancer requires a multi-modality approach – bringing together the most powerful tools in our arsenal to attack tumors from different angles. Tumors are complex, and our strategies must be equally sophisticated.
Our early Phase 2 data combining invikafusp alfa with Gilead’s Trodelvy reflects this vision. In heavily pretreated metastatic breast cancer patients, we’re seeing encouraging signs of activity, including complete and partial responses, as well as disease stabilization.
What’s particularly exciting is the potential of combining precision immunotherapy with precision ADCs-two of the most potent modalities in oncology today. We believe this represents an important step toward the next frontier of cancer treatment.
While still early, these results reinforce our conviction: the future of oncology lies in rationally designed combinations that can ignite the immune system and deliver meaningful outcomes for patients.
Grateful to our patients, investigators, and partners who make this work possible.”
Other articles featuring Zhen Su on OncoDaily.